Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meetin...
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based on guidance from End-of-Phase II meeting with U.S. Food and Drug Administration (FDA): Part A dose confirmation study. Dosing scheme has been agreed with the FDA through Akari’s participation in the Model Informed Drug Development (MIDD) Program.Part B single arm responder-based efficacy study will follow an interim analysis of Part A and a meeting with the FDA. Phase III HSCT-TMA study expected to open by the end of Q4 2019.HSCT-TMA program has received both orphan and Fast Track designations from the FDA.New data from ongoing long-term PNH study shows that all six patients from the Phase II study who were transfusion dependent at entry are now transfusion independent on nomacopan. NEW YORK and LONDON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopha
[Read more]
| Impact snapshot | Event time: | AKTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
AKTX alerts
AKTX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKTX alerts
High impacting Akari Therapeutics Plc ADS news events
Weekly update
A roundup of the hottest topics
AKTX
News
- Akari Therapeutics receives $30M capital commitment [Seeking Alpha]Seeking Alpha
- Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLCGlobeNewswire
- Akari Therapeutics Announces Appointment of Chief Financial OfficerGlobeNewswire
- Akari Therapeutics: An Investment Assessment [Seeking Alpha]Seeking Alpha
- Akari Therapeutics PLC (NASDAQ: AKTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock.MarketBeat
- More
AKTX
SEC Filings
- 7/2/20 - Form SC
- 7/1/20 - Form 6-K
- 7/1/20 - Form 6-K
- AKTX's page on the SEC website
- More